Tipifarnib in Treating Patients With Metastatic Malignant Melanoma

NCT00060125 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

NIH

Sponsor class

Conditions

Recurrent Melanoma
Stage IV Melanoma

Interventions

DRUG: tipifarnib
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)